Cargando…

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

Although TP53 is commonly mutated in transformed follicular lymphoma, mutations are reported in <5% of pretreatment follicular lymphoma (FL) specimens. We assayed archival follicular B-cell non-Hodgkin lymphoma specimens from a completed clinical trial, Southwest Oncology Group S0016, a phase 3 r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burack, W. Richard, Li, Hongli, Adlowitz, Diana, Spence, Janice M., Rimsza, Lisa M., Shadman, Mazyar, Spier, Catherine M., Kaminski, Mark S., Leonard, John P., Leblanc, Michael L., Smith, Sonali M., Friedberg, Jonathan W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Lymphoid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471938/ https://www.ncbi.nlm.nih.gov/pubmed/37379264 http://dx.doi.org/10.1182/bloodadvances.2022009467

Ejemplares similares

TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
por: Johnson, William T., et al.
Publicado: (2023)

Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
por: Griffin, Rosalie, et al.
Publicado: (2023)

Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL
por: Graf, Solomon A., et al.
Publicado: (2022)

Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations
por: Slot, Matilde, et al.
Publicado: (2023)

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
por: Liang, Emily C., et al.
Publicado: (2023)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options
por: Malcikova, Jitka, et al.
Publicado: (2021)

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
por: Gauthier, Jordan, et al.
Publicado: (2022)

Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics
por: Hamadani, Mehdi, et al.
Publicado: (2022)

Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
por: Tun, Aung M., et al.
Publicado: (2022)

Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns
por: Dreval, Kostiantyn, et al.
Publicado: (2023)

Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements
por: Frauenfeld, Leonie, et al.
Publicado: (2022)

Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey
por: Harkins, R. Andrew, et al.
Publicado: (2022)

Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
por: Los-de Vries, G. Tjitske, et al.
Publicado: (2022)

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma
por: Bewicke-Copley, Findlay, et al.
Publicado: (2022)

Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
por: Potnis, Kunal C., et al.
Publicado: (2022)

Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy
por: Rodríguez-Sevilla, Juan Jose, et al.
Publicado: (2022)

SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma
por: Wrench, David, et al.
Publicado: (2011)

Distinct clinical and genetic features of hepatitis B virus–associated follicular lymphoma in Chinese patients
por: Ren, Weicheng, et al.
Publicado: (2022)

Follicular lymphoma subgroups with and without t(14;18) differ in their N-glycosylation pattern and IGHV usage
por: Leich, Ellen, et al.
Publicado: (2021)

Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303
por: Russler-Germain, David A., et al.
Publicado: (2023)

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma
por: Eertink, J. J., et al.
Publicado: (2023)

Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL
por: Levinson, Anya L., et al.
Publicado: (2023)

BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway
por: Butler, Miriam, et al.
Publicado: (2021)

A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma
por: van Bladel, Diede A. G., et al.
Publicado: (2023)

Prognostic model using (18)F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
por: Driessen, Julia, et al.
Publicado: (2023)

BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5
por: Oien, Derek B., et al.
Publicado: (2023)

Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell–like blasts in KMT2A-rearranged leukemia
por: Chen, Changya, et al.
Publicado: (2022)

Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study
por: Brink, Mirian, et al.
Publicado: (2022)

Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma
por: Eertink, Jakoba J., et al.
Publicado: (2022)

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study
por: Haydu, J. Erika, et al.
Publicado: (2022)

IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma
por: Elfrink, Suraya, et al.
Publicado: (2022)

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)

Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation
por: Merryman, Reid W., et al.
Publicado: (2022)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?
por: Imber, Brandon S., et al.
Publicado: (2021)

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies
por: Thomalla, D., et al.
Publicado: (2022)

Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma
por: Little, Jessica S., et al.
Publicado: (2022)

Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001
por: Tran, Thai Hoa, et al.
Publicado: (2022)

Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity
por: Le, Kang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n4hoe5b76105r6p3mrmn0eme82